Autolus Therapeutics announces abstract submitted to ACR Convergence 2025

Autolus Therapeutics (AUTL) announces the online publication of an abstract submitted to the American College of Rheumatology, ACR, Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which will include updated follow up from the CARLYSLE study in patients with severe refractory systemic lupus erythematosus, srSLE. Summary: Initial findings from the ongoing CARLYSLE study of obe-cel in srSLE show a manageable safety profile, with no dose limiting toxicities, immune effector cell-associated neurotoxicity syndrome or Grade greater than or equal to2 cytokine release syndrome. SLEDAI-2K score reduction and clinical benefit were observed in all patients. In addition, three patients who had a complete renal response. Updated data will be presented at the conference.